Fieldfisher advised on US$1.3 billion (€1.25 billion) of venture financing deals in 2021

Fieldfisher’s European venture capital and growth equity team recorded a record year for venture investment deal value in 2021.
 
The firm’s 2021 deal portfolio represented its expanded capabilities in growth equity, which complement its existing expertise in venture capital and venture debt, and reflected the broader strength of the global and European equity markets last year.

The vast proportion of deal value came from the Series B+ growth financing  (and venture debt) end of the market,  as Fieldfisher increased its instructions from larger, well-established but still growing companies and funds.

Fieldfisher also increased the amount of work it did for funds. In particular, it saw further growth in the amount of US VC funding deployed to European companies.

Technology remained the busiest business sector for Fieldfisher’s venture financing team, accounting for over US$738 million (€700 million, or 59% of total deal value).

This was supplemented by robust activity in life sciences and healthcare, with transactions in this sector making up over US$318 million (€301 million, or 25% of deal value). Other deals were spread over sectors including energy and natural resources, food and beverage and leisure.

For a breakdown of the firm's VC deals and analysis by sector and funding stage, download a copy of Fieldfisher's VC Wrap 2021.

Commenting on Fieldfisher’s 2021 VC deal performance, corporate partner Tom Ward said:

"2021 was another excellent year for our international venture financing group, which encompasses venture capital, growth equity and venture debt.

"The portfolio of entrepreneurial businesses we work with continues to grow, as we bring on new clients alongside our work for longstanding clients as they progress on their growth journeys, right up to growth funding and exit, where we saw an increase in deal activity and value."